LABU is a 3X leveraged fund that has disappointed the biotech bulls. The sector looks beaten and perhaps cheap relative to long-term prospects. LABU can work for medium term returns if two ...
Biotech stocks have pulled back and offer better risk to reward for investors, Direxion Daily S&P Biotech Bull 3x Shares ETF is a popular way to trade them. M&A is likely to drive prices for mid-cap ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback